Chad C. Bjorklund

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide

Yuan Xiao Zhu, Esteban Braggio, Chang-Xin Shi et al. · Blood · 2011 · 591 citations · Full text

Rate of CRL4CRBN substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4

Chad C. Bjorklund, Ling Lu, Jian Kang et al. · Blood Cancer Journal · 2015 · 211 citations · Full text

CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL

Patrick R. Hagner, Hon‐Wah Man, Celia Fontanillo et al. · Blood · 2015 · 197 citations · Full text

Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN

Chad C. Bjorklund, Jian Kang, Michael Amatangelo et al. · Leukemia · 2019 · 188 citations · Full text

Hematological Malignancy, Dysregulated Crbn, Immunostimulatory Activities +8

Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma

Deborah J. Kuhn, Zuzana Berkova, Richard J. Jones et al. · Blood · 2012 · 172 citations · Full text